查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847799

按检测方法、病原体类型、最终用户和样本类型分類的医疗保健相关感染疾病诊断市场—2025-2032年全球预测

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，医疗保健相关感染疾病诊断市场将成长至 84.7 亿美元，复合年增长率为 8.60%。

主要市场统计数据
基准年 2024 43.7亿美元
预计年份：2025年 47.6亿美元
预测年份：2032年 84.7亿美元
复合年增长率 (%) 8.60%

制定了一系列紧迫的临床、营运和政策要务，以加速采用下一代诊断技术，从而减少医疗保健相关感染疾病，改善病患安全结果。

医疗相关感染疾病对临床医生、实验室专业人员和医疗系统而言都是一项持续且不断变化的挑战。快速、准确的诊断对于及时进行患者管理、抗菌药物管理和感染预防项目至关重要。随着临床路径的日益整合和住院容量压力的加剧，诊断效能和工作流程的兼容性在医疗服务中变得越来越关键。

这种应用从三个相互关联的视角建构了诊断格局：临床效用、操作可行性和政策契合度。临床医生需要可操作的结果来立即做出治疗决策。实验室管理者必须在保持严格品管的同时，平衡检测量、週转时间和成本。政策制定者和感染控制负责人需要数据来支持计画干预措施，并确保其符合报销和监管要求。

因此，诊断生态系统的评判标准不再仅限于分析灵敏度，而是要看其能否整合到电子健康记录、支持抗菌药物管理目标以及抵御供应链中断。这种整合为深入分析技术变革、监管发展、商业性应对措施和实用建议奠定了基础，这些内容将在后续章节中展开。

检验正在重塑医疗保健环境中诊断工作流程、实验室操作和感染预防策略的变革性技术、监管和行为转变

诊断领域正经历着深刻的变革，这主要由技术进步、监管环境变化以及不断涌现的临床需求所驱动。分子生物学技术正从专业的标准实验室转移到更贴近患者的诊疗环境，从而实现更早的病原体检测和更快速的治疗调整。同时，免疫测量平台也在不断发展，变得更加自动化和互联互通，从而减少人工操作，并在高效能环境下提高检测结果的可重复性。

法律规范和品质预期正在不断发展，更加重视临床检验和实际应用效能，这影响供应商设计检测方法的方式以及实验室实施新检测方法的方式。临床医生在抗菌素抗药性和感染预防意识的提高推动了行为转变，促使他们寻求能够提供及时、可操作资讯的诊断方法，而不仅仅是孤立的分析结果。

在营运层面，自动化和数位化整合正在重塑实验室工作流程，规范流程以提高可靠性，同时创造机会将熟练的员工重新部署到更高价值的任务中。总而言之，这些动态意味着，诊断的评估不仅要看其准确性，还要看其如何促进医疗服务、减少不合理使用抗生素以及增强系统韧性。

分析2025年美国关税对供应链、定价、製造地选择和临床采购行为的多面向影响

关税和贸易政策的变化会对诊断供应链产生连锁反应，影响零件、耗材和组装设备。 2025年，关税制度的变化影响了试剂生产商和仪器组装的采购决策，促使一些机构实现供应商多元化并重新评估库存策略。对于实验室管理人员和采购团队而言，这些变化使得他们在维持持续检测能力的同时，更加重视控製成本。

製造商采取了各种缓解策略，包括将某些生产步骤转移到近岸地区、优化材料清单以减少暴露的组件以及与供应商谈判长期合约以稳定投入价格，而临床相关人员则强调了可行的替代方案和交叉检验的工作流程的重要性，以确保在首选检测套组供应有限的情况下，临床工作的连续性。

这种更广泛的政策转变有可能加速整个诊断生态系的结构性变革。为此，医疗系统和实验室网路正日益将供应链风险评估纳入技术采纳决策，在采购合约中製定紧急应变计画，并倡导贸易政策的明确性，以减少营运中的不确定性。

提供精确的细分洞察，将检测技术、病原体特异性诊断、终端使用者能力和检体类型与临床效用和营运规划连结。

对市场区隔进行详细分析，有助于深入了解价值创造点和营运摩擦点。依检测方法划分，市场可分为免疫检测、微生物学和分子诊断。免疫检测包括化学冷光免疫检测、酵素连结免疫吸附试验 (ELISA) 和侧向流动检测法，每种方法在通量、灵敏度和易用性方面各有重点。微生物学工作流程包括培养、显微镜检查和药敏试验，其中培养可细分为需氧培养和厌氧培养，这会影响实验室布局和培养方案。分子诊断包括等温扩增、聚合酶炼式反应 (PCR) 和定序，每种方法对基础设施、人员能力和数据解读的要求各不相同。

根据病原体的类型，细菌、真菌、寄生虫和病毒的诊断策略各不相同。细菌检测通常针对艰难梭菌、大肠桿菌、绿脓桿菌和金黄色葡萄球菌，快速鑑定和药敏试验结果可直接影响抗生素治疗。真菌困难梭状芽孢桿菌主要针对曲霉菌、念珠菌和新型隐球菌，这些病原体的检测通常需要专门的检测方法和临床相关性分析。寄生虫检测，例如疟原虫和弓形虫的检测，往往侧重于特定的临床情况；而病毒检测，例如冠状病毒、流感病毒、诺罗病毒和呼吸道融合细胞病毒的检测，则涵盖常规监测和急诊决策。

最终用户的特征决定了技术的采纳和实施管道。诊断实验室优先考虑规模、认证和实验室间可比性，包括独立实验室和参考实验室。同时，医院重视与临床团队的整合，并透过临床病理和微生物实验室实现快速的住院病患工作流程。诊所、急诊和长期照护机构等即时照护现场需要紧凑的平台、简化的工作流程和快速的周转时间，这些因素会影响检测方法的选择和验证策略。

检体类型——血液（血清和全血）、脑脊髓液、呼吸道检体（支气管肺泡灌洗液、鼻咽拭子和痰液）、尿液（导尿管尿和中段尿）以及伤口拭子（深层组织拭子和浅表拭子）——进一步决定了分析前管理、物流和分析灵敏度阈值。检测方法、目标病原体、最终用户和样本类型之间的相互作用构成了一个多维决策矩阵，相关人员在确定投资优先顺序、选择平台和设计交付管道时必须权衡这一矩阵。

解读美洲、欧洲、中东和非洲以及亚太地区的区域动态，以揭示能力优势、招募模式和策略市场进入考量。

区域动态对诊断技术的普及、监管协调和供应链架构有显着影响。在美洲，成熟的检测基础设施和完善的报销管道催生了对快速、高通量解决方案以及床边检测的需求。该地区的相关人员通常优先考虑整合性、可扩展性和供应商支援的模式。相反，由于监管环境、资源限制和公共卫生优先事项的差异，欧洲和中东/非洲的普及模式有所不同。在许多市场，集中式参考侦测与快速照护现场部署并存，以满足紧急需求。

亚太地区的能力差异显着，既有高度发展的都市实验室网络，也有难以取得复杂平台的地区。这种多样性正在影响製造商的策略，使其围绕模组化系统、语言适配的软体以及本地伙伴关係关係展开，以确保系统的实施和可维护性。在整个亚太地区，采购行为、公共卫生需求和基础设施投资都会影响诊断的优先顺序，而互联互通和资料互通性正日益被视为区域监测和临床决策的关键推动因素。

因此，策略性进入和规模化决策必须使当地监管管道、物流限制和临床实践规范与目标诊断解决方案的技术特性相符。能够根据当地实际情况调整产品供应的相关人员，将更有利于实现持续的临床应用和系统性影响。

透过对主要企业概况和竞争动态的分析，揭示影响诊断生态系统的产品系列、伙伴关係策略、创新管道和商业化方法。

企业行动和竞争定位是决定医疗机构诊断能力未来发展方向的核心因素。领先的製造商正着力建构产品组合策略，力求在高性能实验室系统、照护现场和床边检测平台之间取得平衡，从而兼顾集中式检测的经济效益和分散式临床需求。策略伙伴关係与分销协议拓展了业务覆盖范围，并提供了在地化的服务能力；而创新研发则体现了多重检测能力、自动化和数位化连接等优先发展方向。

产品差异化日益不仅取决于侦测分析效能，还取决于端到端的价值提案，包括仪器执行时间、耗材物流、云端资料解读以及实验室人员培训计画。那些投资于产生可靠的上市后证据并与医疗系统合作进行试点计画的公司，将赢得临床使用者和采购团队的信任。此外，透过减少一次性塑胶的使用和优化试剂包装来提升永续性的竞争优势，也将影响采购偏好和长期合作关係的维护。

随着商业性参与企业适应不断变化的政策环境和供应链压力，有关製造规模、平台模组化和服务生态系统的策略选择将决定医疗保健系统部署和扩展诊断解决方案以改善感染控制的难易程度。

为产业领导者提供切实可行、影响深远的建议，以优化诊断部署、增强供应弹性，并使临床工作流程与感染控制要求保持一致。

针对产业领导者的实际建议应将策略洞察转化为采购、实验室营运和临床管治等各环节的可操作步骤。首先，在评估新平台时，应优先考虑互通性和连接性，以确保结果能够与电子健康记录、决策支援工具和监测系统无缝整合。其次，应将供应链风险评估纳入采购流程，评估替代试剂来源、前置作业时间差异以及供应商紧急时应对计画，以避免在供应短缺期间出现服务中断。

第三，我们正在统一联网实验室的验证和确认通讯协定，以便在保持可比性和品质保证的同时，实现新检测方法的快速规模化应用。第四，我们正在加大对人才队伍建设的投入，确保实验室人员接受分子和数位化工作流程的训练。第五，我们对新诊断方法采取分阶段引入的方式，包括临床测试、多学科审查和回馈机制，以了解其实际表现和对工作流程的影响。

最后，为了降低医疗系统客户的实施风险，应尽可能使商业协议与以结果为导向的指标保持一致，包括运作保证、配套服务以及共同创建上市后证据。这些措施结合起来可以加速负责任地部署诊断创新技术，从而大幅减少感染相关的危害。

我们描述了一种严谨的混合调查方法，该方法结合了主要相关人员访谈、实验室工作流程观察和二手证据的整合，以支持可靠的研究结果。

本分析采用混合研究途径，整合一手和二手证据，以得出可操作的见解。主要定性资料透过对实验室主任、感染疾病临床医生、采购负责人和监管专家进行结构化访谈收集，以了解实践现状、未满足的需求和实施障碍。此外，还对不同环境下的实验室工作流程进行了直接观察，以了解分析前变异性、通量限制和整合挑战。

我们从同行评审文献、监管指导文件和製造商技术规格中收集了二次性证据，以检验检测属性并检验性能声明。在条件允许的情况下，比较评估采用了已发布的分析绩效指标和已记录的案例研究，以便为培训、维护和连接提供实际参考。

透过标准化的访谈指南、主题编码的交叉检验以及对解释性综合中所用假设的透明记录，确保了分析的严谨性。最终形成的方法论优先考虑操作相关性和临床适用性，确保结论能够为负责采购、实验室操作和感染控制实践的决策者提供切实可行的指导。

这份综合报告提炼了关键见解，并将其转化为连贯的策略要点，供医疗保健领导者、实验室管理者和政策制定者采取果断行动。

这篇总结性综述将分析提炼为对医疗保健领导者、实验室管理者和政策制定者俱有策略意义的要点。诊断只有在临床决策窗口期内提供可操作的信息，并且实验室工作流程的设计能够维持高品质、及时的产出时，才能发挥最大的作用。技术创新——特别是分子方法和自动化免疫检测——为转变诊断模式创造了机会，但成功实施取决于互通性、人员准备和供应链的稳健性。

如果政策和采购机制能够奖励真实世界证据的生成、支持人才队伍建设，并在合约中纳入紧急应变计画，就能加速研发进程。技术上更胜一筹但与当地工作流程、监管环境或样本物流不符的解决方案，难以实现持续推广应用。因此，采取将临床需求、实验室能力和商业模式结合的整体方法，对于在感染预防和患者疗效方面取得可衡量的改进至关重要。

综上所述，这些研究结果表明，综合规划、跨职能协作和适应性筹资策略对于将诊断创新转化为临床和营运影响至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 在医院环境中整合快速分子诊断检测方法来识别多重抗药性细菌
  • 实施人工智慧驱动演算法以早期检测术后患者的手术部位感染
  • 在门诊环境中推广照护现场CRISPR 的即时检测方法，以快速识别医院获得性病原体
  • 在加护病房采用多重PCR检测板同时检测细菌及病毒性医疗相关感染疾病
  • 整合即时抗菌药物敏感性检测平台，以优化加护治疗中的抗菌药物管理
  • 开发用于即时追踪医院获得性感染爆发的高通量全基因组定序工作流程
  • 引入远距感染疾病咨询服务，以减少偏远地区医疗机构的诊断延误。
  • 奈米技术增强型生物感测器在住院病患血液感染疾病连续监测的应用
  • 引进基于云端基础的监测平台，用于追踪医院内多重抗药性细菌的传播模式
  • 利用机器人技术加速自动化微生物实验室病原体鑑定和报告的成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 医疗保健相关感染疾病市场：检测方法

  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 横向流动化验
  • 微生物学
    • 文化
      • 需氧培养
      • 厌氧培养
    • 显微镜
    • 敏感性测试
  • 分子诊断
    • 等温扩增
    • PCR
    • 顺序

9. 按病原体类型分類的医疗保健相关感染疾病诊断市场

  • 细菌
    • 困难梭状芽孢桿菌
    • 大肠桿菌
    • 铜绿假单胞菌
    • 金黄色葡萄球菌
  • 真菌
    • 曲菌
    • 念珠菌
    • 新型隐球菌
  • 寄生虫
    • 疟疾原虫
    • 弓形虫
  • 病毒性的
    • 新冠病毒
    • 流感病毒
    • 诺罗病毒
    • 呼吸道融合病毒（RSV）

第十章 按最终用户分類的医疗保健相关感染疾病诊断市场

  • 诊断实验室
    • 独立实验室
    • 参考实验室
  • 医院
    • 临床病理实验室
    • 微生物实验室
  • 照护现场
    • 诊所
    • 急诊部
    • 长期照护机构

第十一章 依样本类型分類的医疗保健相关感染疾病诊断市场

  • 血
    • 血清
    • 全血
  • 脑脊髓液
  • 呼吸系统
    • 支气管肺泡灌洗
    • 鼻咽拭子
    • 痰
  • 尿
    • 导尿管尿液
    • 中段尿
  • 伤口拭子
    • 深层组织样本
    • 表面拭子

12. 各地区医疗保健相关感染疾病诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 医疗保健相关感染疾病诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国医疗保健相关感染疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Diagnostics International AG
    • Abbott Laboratories
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Becton, Dickinson and Company
    • bioMerieux SA
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • DiaSorin SpA
Product Code: MRR-8760467AA424

The Healthcare-associated Infectious Disease Diagnostics Market is projected to grow by USD 8.47 billion at a CAGR of 8.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.37 billion
Estimated Year [2025] USD 4.76 billion
Forecast Year [2032] USD 8.47 billion
CAGR (%) 8.60%

Framing the urgent clinical, operational, and policy imperatives driving next-generation diagnostic adoption to curb healthcare-associated infections and improve patient safety outcomes

Healthcare-associated infectious diseases represent a persistent and evolving challenge for clinicians, laboratory professionals, and health systems alike. Rapid and accurate diagnostics are core to timely patient management, antimicrobial stewardship, and infection prevention programs. As clinical pathways become more integrated and pressure on inpatient capacity intensifies, diagnostic performance and workflow fit are increasingly decisive factors in care delivery.

This introduction frames the diagnostic landscape through three interlocking lenses: clinical utility, operational feasibility, and policy alignment. Clinicians require actionable results that inform immediate treatment decisions. Laboratory managers must balance throughput, turnaround time, and cost while maintaining rigorous quality controls. Policy makers and infection control leaders need data that supports programmatic interventions and aligns with reimbursement and regulatory imperatives.

Consequently, the diagnostics ecosystem is no longer judged by analytic sensitivity alone; it is evaluated by its ability to integrate into electronic medical records, to support antimicrobial stewardship objectives, and to withstand supply chain disruption. This synthesis sets the stage for deeper analysis of technological shifts, regulatory currents, commercial responses, and pragmatic recommendations that follow in subsequent sections.

Examining the transformative technological, regulatory, and behavioral shifts reshaping diagnostic workflows, laboratory practices, and infection prevention strategies across care settings

The diagnostic landscape is undergoing a profound transformation driven by converging technological advances, shifting regulatory expectations, and newly elevated clinical demands. Molecular methods have moved from specialized reference labs into near-patient settings, enabling earlier detection of pathogens and faster therapeutic alignment. At the same time, immunoassay platforms are evolving to offer greater automation and connectivity, reducing manual steps and enhancing reproducibility across high-throughput environments.

Regulatory frameworks and quality expectations have evolved to prioritize clinical validation and real-world performance, which influences how vendors design trials and how laboratories implement new assays. Behavioral shifts among clinicians-driven by heightened awareness of antimicrobial resistance and infection prevention targets-have increased demand for diagnostics that deliver timely, actionable intelligence rather than isolated analytic results.

Operationally, automation and digital integration are reshaping laboratory workflows, creating opportunities to reassign skilled staff to higher-value tasks while standardizing processes to improve reliability. These dynamics collectively point to a landscape in which diagnostics are evaluated not only on accuracy but on how they accelerate care, reduce inappropriate antimicrobial use, and enhance system resilience.

Analyzing the multifaceted implications of United States tariff actions in 2025 on supply chains, pricing dynamics, manufacturing location decisions, and clinical procurement behaviors

Tariff actions and trade policy changes have the potential to reverberate through diagnostic supply chains, affecting components, consumables, and assembled instruments. In 2025, shifts in tariff regimes influenced sourcing decisions for reagent manufacturers and instrument assemblers, prompting some organizations to reassess supplier diversification and inventory strategies. For laboratory managers and procurement teams, these developments brought renewed attention to cost containment while maintaining uninterrupted testing capacity.

Manufacturers responded through a range of mitigation strategies, including near-shoring certain production stages, optimizing bill-of-materials to reduce exposed components, and negotiating long-term supplier contracts to stabilize input pricing. Meanwhile, clinical stakeholders emphasized the importance of validated alternatives and cross-validated workflows to ensure clinical continuity when preferred test kits are constrained.

The broader implication is that policy shifts can accelerate structural change across the diagnostics ecosystem. In response, health systems and laboratory networks are increasingly incorporating supply-chain risk assessments into technology adoption decisions, embedding contingency plans into procurement contracts, and advocating for clarity in trade policy to reduce operational uncertainty.

Delivering incisive segmentation insights that connect test methodologies, pathogen-specific diagnostics, end user capacities, and sample type considerations to clinical utility and operational planning

A granular view of segmentation offers practical insight into where value is created and where operational friction can arise. By test method, the landscape divides among immunoassays, microbiology, and molecular diagnostics. Immunoassays encompass chemiluminescent immunoassays, ELISA, and lateral flow assays, each offering different balances of throughput, sensitivity, and ease of use. Microbiology workflows include culture, microscopy, and sensitivity testing, with culture further differentiated into aerobic and anaerobic techniques that influence laboratory layout and incubation protocols. Molecular diagnostics feature isothermal amplification, PCR, and sequencing approaches; each method carries distinct infrastructure, personnel competency, and data-interpretation requirements.

When considering pathogen type, diagnostic strategies differ for bacterial, fungal, parasitic, and viral agents. Bacterial testing frequently targets organisms such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, where rapid identification and susceptibility insights directly affect antimicrobial therapy. Fungal diagnostics address Aspergillus species, Candida species, and Cryptococcus neoformans, which often require specialized assays and clinical correlation. Parasitic testing, including malaria parasites and Toxoplasma gondii, tends to be concentrated in specific clinical contexts, while viral testing for agents such as coronaviruses, influenza viruses, norovirus, and respiratory syncytial virus spans both routine surveillance and acute care decision-making.

End user characteristics shape adoption and implementation pathways. Diagnostic laboratories, including both independent and reference labs, prioritize scale, accreditation, and inter-laboratory comparability, whereas hospitals, through clinical pathology and microbiology laboratories, emphasize integration with clinical teams and rapid inpatient workflows. Point-of-care contexts such as clinics, emergency departments, and long-term care facilities demand compact platforms, simplified workflows, and rapid turnaround, which in turn influence assay format choices and validation strategies.

Sample type considerations-blood (serum and whole blood), cerebrospinal fluid, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (deep tissue and surface swabs)-further dictate pre-analytical controls, transport logistics, and analytic sensitivity thresholds. The interplay among test method, pathogen target, end user, and sample type creates a multidimensional decision matrix that stakeholders must navigate when prioritizing investments, selecting platforms, and designing implementation pathways.

Interpreting regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific to reveal capacity strengths, adoption patterns, and strategic market entry considerations

Regional dynamics materially affect diagnostic adoption, regulatory alignment, and supply chain architecture. In the Americas, maturity in laboratory infrastructure and established reimbursement pathways create a demand environment for rapid, high-throughput solutions alongside near-patient testing; stakeholders here often prioritize integration, scalability, and vendor support models. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory variation, resource constraints, and diverse public health priorities drive differential adoption patterns; in many markets, centralized reference testing coexists with pockets of rapid point-of-care rollouts in response to acute needs.

Asia-Pacific is characterized by a wide range of capabilities, from highly advanced metropolitan laboratory networks to regions with limited access to complex platforms. This diversity shapes manufacturer strategies around modular systems, language-appropriate software, and local partnerships to ensure adoption and serviceability. Across all regions, procurement behaviors, public health imperatives, and infrastructure investments influence how diagnostics are prioritized, with connectivity and data interoperability increasingly seen as cross-cutting enablers for regional surveillance and clinical decision-making.

Consequently, strategic entry and scale-up decisions must reconcile regional regulatory pathways, logistics constraints, and clinical practice norms with the technical attributes of targeted diagnostic solutions. Stakeholders that align product offerings with regional operational realities are better positioned to achieve sustained clinical uptake and system impact.

Profiling leading companies and competitive behaviors to highlight product portfolios, partnership strategies, innovation pipelines, and commercialization approaches that influence diagnostic ecosystems

Company behavior and competitive positioning are central determinants of how diagnostic capabilities evolve across care settings. Leading manufacturers emphasize a portfolio approach that balances high-throughput laboratory systems with point-of-care and near-patient platforms, thereby addressing both centralized testing economies and decentralized clinical demands. Strategic partnerships and distribution agreements expand geographic reach and provide local serviceability, while innovation pipelines reflect priorities such as multiplexing capability, automation, and digital connectivity.

Product differentiation increasingly hinges on end-to-end value propositions: not only the analytic performance of assays but also instrumentation uptime, consumable logistics, cloud-enabled data interpretation, and training programs for laboratory staff. Firms that invest in robust post-market evidence generation and that collaborate with health systems on implementation pilots secure credibility with clinical users and procurement teams. Additionally, a competitive emphasis on sustainability-through reduced single-use plastics and optimized reagent packaging-affects procurement preferences and long-term relationship management.

As commercial players adapt to evolving policy environments and supply-chain pressures, their strategic choices around manufacturing footprints, platform modularity, and service ecosystems will determine how readily health systems can deploy and scale diagnostic solutions in pursuit of improved infection management.

Presenting actionable, high-impact recommendations for industry leaders to optimize diagnostic deployment, strengthen supply resilience, and align clinical workflows with infection control imperatives

Actionable recommendations for industry leaders must translate strategic insight into implementable steps across procurement, laboratory operations, and clinical governance. First, prioritize interoperability and connectivity when evaluating new platforms so results can seamlessly integrate with electronic medical records, decision support tools, and surveillance systems; this reduces cognitive load on clinicians and supports stewardship programs. Second, embed supply-chain risk assessments into procurement cycles by evaluating alternate reagent sources, lead-time variability, and vendor contingency plans to avoid service disruptions during periods of constrained supply.

Third, standardize validation and verification protocols across networked laboratories to enable rapid scale-up of new assays while maintaining comparability and quality assurance. Fourth, invest in workforce development to ensure laboratory staff are trained in molecular and digital workflows; reallocating staff from repetitive tasks to higher-value data interpretation improves system resilience. Fifth, adopt a phased implementation approach for novel diagnostics that includes clinical pilots, multidisciplinary reviews, and feedback loops that capture real-world performance and workflow impact.

Finally, align commercial contracting with outcomes-oriented metrics where feasible, incorporating uptime guarantees, bundled service offerings, and joint post-market evidence generation to de-risk adoption for health system customers. Taken together, these steps will accelerate responsible deployment of diagnostic innovations that materially reduce infection-related harms.

Explaining a rigorous mixed-methods research methodology combining primary stakeholder interviews, laboratory workflow observations, and secondary evidence synthesis to underpin credible findings

This analysis is grounded in a mixed-methods research approach that synthesizes primary and secondary evidence to generate actionable insight. Primary qualitative data were gathered through structured interviews with laboratory directors, infectious disease clinicians, procurement officers, and regulatory experts to capture operational realities, unmet needs, and adoption barriers. These interviews were complemented by direct observations of laboratory workflows in diverse settings to understand pre-analytical variability, throughput constraints, and integration challenges.

Secondary evidence was curated from peer-reviewed literature, regulatory guidance documents, and manufacturer technical specifications to validate assay attributes and to triangulate performance claims. Where possible, comparative assessments leveraged published analytic performance metrics and documented implementation case studies to inform practical considerations around training, maintenance, and connectivity.

Analytic rigor was maintained through standardized interview guides, cross-validation of thematic coding, and transparent documentation of assumptions used in interpretive synthesis. The resulting methodology privileges operational relevance and clinical applicability, ensuring that conclusions are actionable for decision-makers responsible for procurement, laboratory operations, and infection control policy.

Concluding synthesis that distills key insights into coherent strategic takeaways aimed at healthcare leaders, laboratory managers, and policy makers for decisive action

This concluding synthesis distills the analysis into strategic takeaways for healthcare leaders, laboratory managers, and policy makers. Diagnostics are most impactful when they deliver actionable intelligence within clinical decision windows and when laboratory workflows are designed to sustain high-quality, timely outputs. Technological innovation-particularly in molecular methods and automated immunoassays-creates opportunities to shift diagnostic paradigms, but successful adoption depends on interoperability, workforce readiness, and supply-chain robustness.

Policy and procurement levers can accelerate deployment when they incentivize real-world evidence generation, support workforce development, and incorporate contingency planning into contracts. Regional dynamics and end-user characteristics matter: solutions that are technically excellent but misaligned with local workflow, regulatory realities, or sample logistics will struggle to achieve sustained uptake. Therefore, a holistic approach that aligns clinical needs, laboratory capabilities, and commercial models is essential for delivering measurable improvements in infection prevention and patient outcomes.

Taken together, the findings underscore that integrated planning, cross-functional collaboration, and adaptive procurement strategies are central to translating diagnostic innovation into clinical and operational impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of rapid molecular diagnostic assays for multidrug-resistant organism identification in hospital settings
  • 5.2. Implementation of AI-driven algorithms for early detection of surgical site infections in postoperative patients
  • 5.3. Expansion of point-of-care CRISPR-based assays for rapid identification of hospital-acquired pathogens in outpatient settings
  • 5.4. Adoption of multiplex PCR panels for simultaneous detection of bacterial and viral healthcare-associated infections in critical care units
  • 5.5. Integration of real-time antimicrobial susceptibility testing platforms to optimize antibiotic stewardship in intensive care
  • 5.6. Development of high-throughput whole genome sequencing workflows to track nosocomial infection outbreaks in real time
  • 5.7. Implementation of teleinfectious disease consultation services to reduce diagnosis delays in remote healthcare facilities
  • 5.8. Emergence of nanotechnology-enhanced biosensors for continuous monitoring of bloodstream infections in hospitalized patients
  • 5.9. Deployment of cloud-based surveillance dashboards for cross-hospital tracking of multidrug-resistant organism transmission patterns
  • 5.10. Cost-benefit analysis of automated microbiology laboratories leveraging robotics to accelerate pathogen identification and reporting

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescent Immunoassay
    • 8.1.2. ELISA
    • 8.1.3. Lateral Flow Assays
  • 8.2. Microbiology
    • 8.2.1. Culture
      • 8.2.1.1. Aerobic Culture
      • 8.2.1.2. Anaerobic Culture
    • 8.2.2. Microscopy
    • 8.2.3. Sensitivity Testing
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. PCR
    • 8.3.3. Sequencing

9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

  • 9.1. Bacterial
    • 9.1.1. Clostridium Difficile
    • 9.1.2. Escherichia Coli
    • 9.1.3. Pseudomonas Aeruginosa
    • 9.1.4. Staphylococcus Aureus
  • 9.2. Fungal
    • 9.2.1. Aspergillus Species
    • 9.2.2. Candida Species
    • 9.2.3. Cryptococcus Neoformans
  • 9.3. Parasitic
    • 9.3.1. Malaria Parasites
    • 9.3.2. Toxoplasma Gondii
  • 9.4. Viral
    • 9.4.1. Coronavirus
    • 9.4.2. Influenza Virus
    • 9.4.3. Norovirus
    • 9.4.4. Respiratory Syncytial Virus

10. Healthcare-associated Infectious Disease Diagnostics Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Independent Laboratories
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals
    • 10.2.1. Clinical Pathology Laboratories
    • 10.2.2. Microbiology Laboratories
  • 10.3. Point Of Care
    • 10.3.1. Clinics
    • 10.3.2. Emergency Departments
    • 10.3.3. Long Term Care Facilities

11. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

  • 11.1. Blood
    • 11.1.1. Serum
    • 11.1.2. Whole Blood
  • 11.2. Cerebrospinal Fluid
  • 11.3. Respiratory
    • 11.3.1. Bronchoalveolar Lavage
    • 11.3.2. Nasopharyngeal Swabs
    • 11.3.3. Sputum
  • 11.4. Urine
    • 11.4.1. Catheterized Urine
    • 11.4.2. Midstream Urine
  • 11.5. Wound Swabs
    • 11.5.1. Deep Tissue Samples
    • 11.5.2. Surface Swabs

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Danaher Corporation
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. bioMerieux SA
    • 15.3.8. QIAGEN N.V.
    • 15.3.9. Bio-Rad Laboratories, Inc.
    • 15.3.10. DiaSorin S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032